Vmn1r170 Inhibitors
Vmn1r170, a member of the vomeronasal receptor family, holds a critical role in pheromone sensing and mediating social and reproductive behaviors. Positioned within the vomeronasal organ, Vmn1r170 functions as a chemosensory receptor, responding to specific chemical cues in the environment and translating them into neuronal signals that drive species-specific behaviors. The inhibition of Vmn1r170 involves intricate molecular events influenced by various chemicals acting either directly or indirectly on the receptor.
Direct inhibitors, such as Wortmannin and U0126, disrupt specific cellular processes crucial for proper Vmn1r170 functioning by targeting the PI3K-Akt and MAPK pathways, respectively. Indirect inhibitors, like SB-431542 and LY411575, modulate broader cellular pathways intersecting with those involved in Vmn1r170 regulation, such as the TGF-β and Notch signaling pathways. These diverse inhibitors highlight the complex regulatory mechanisms that govern Vmn1r170 activity, unveiling potential strategies for modulating chemosensory responses in the intricate tapestry of species-specific communication. The exploration of such chemical inhibitors not only enriches our understanding of Vmn1r170 inhibition but also provides valuable insights into the interplay between cellular pathways and the intricate regulation of vomeronasal receptor function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a potent PI3K inhibitor, directly impedes Vmn1r170 by disrupting the PI3K-Akt pathway. This interference hinders downstream elements critical for Vmn1r170 expression, leading to a decrease in its functional activity within the vomeronasal organ. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a specific PI3K inhibitor, directly targets the PI3K-Akt pathway, impacting Vmn1r170. This inhibition alters downstream signaling cascades, adversely affecting the regulation of Vmn1r170 expression and its associated cellular processes, ultimately leading to a decrease in the receptor's functional capacity within the vomeronasal organ. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, a MEK1/2 inhibitor, directly impedes Vmn1r170 by disrupting the MAPK pathway. This interference alters downstream elements crucial for Vmn1r170 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542, a selective TGF-β type I receptor inhibitor, indirectly hampers Vmn1r170 expression by obstructing the TGF-β signaling pathway. This disruption influences downstream elements affecting gene transcription related to Vmn1r170 activity, resulting in a decrease in the receptor's functional capacity within the vomeronasal organ. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059, a MEK inhibitor, directly impacts Vmn1r170 by disrupting the MAPK pathway. This interference alters downstream signaling cascades crucial for Vmn1r170 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
LY411575 | 209984-57-6 | sc-364529 sc-364529A | 10 mg 50 mg | $198.00 $473.00 | 6 | |
LY411575, a γ-secretase inhibitor, indirectly influences Vmn1r170 by disrupting the Notch signaling pathway. This interference alters downstream targets crucial for Vmn1r170 expression and function, resulting in a decrease in the receptor's functional capacity within the vomeronasal organ. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, directly impedes Vmn1r170 by disrupting the JNK signaling pathway. This interference alters downstream elements crucial for Vmn1r170 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 202190, a p38 MAPK inhibitor, directly targets Vmn1r170 by disrupting the p38 MAPK pathway. This interference alters downstream signaling cascades crucial for Vmn1r170 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $89.00 $275.00 | 9 | |
LY2109761, a TGF-β receptor inhibitor, indirectly hampers Vmn1r170 expression by disrupting the TGF-β signaling pathway. This disruption influences downstream elements affecting gene transcription related to Vmn1r170 activity, resulting in a decrease in the receptor's functional capacity within the vomeronasal organ. | ||||||
TAK 715 | 303162-79-0 | sc-362799 sc-362799A | 10 mg 50 mg | $185.00 $781.00 | ||
TAK-715, a p38 MAPK inhibitor, directly impacts Vmn1r170 by disrupting the p38 MAPK pathway. This interference alters downstream signaling cascades crucial for Vmn1r170 expression and function, leading to a decrease in the receptor's functional activity within the vomeronasal organ. | ||||||